Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR-defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi) but they eventually acquire resistance. Preclinical studies yielded several PARPi resist...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv
Main Authors: Bhin, Jinhyuk, Dias, Mariana Paes, Gogola, Ewa, Rolfs, Frank, Piersma, Sander R., de Bruijn, Roebi, de Ruiter, Julian R., van den Broek, Bram, Duarte, Alexandra A., Sol, Wendy, van der Heijden, Ingrid, Bakker, Lara, Kaiponen, Taina S., Lieftink, Cor, Morris, Ben, Beijersbergen, Roderick L., van de Ven, Marieke, Jimenez, Connie R., Wessels, Lodewyk F. A., Rottenberg, Sven, Jonkers, Jos
Format: Paper
Language:English
Published: Cold Spring Harbor Laboratory 07.09.2022
Edition:1.1
Subjects:
Cancer Biology
homologous recombination
PARP inhibitor
multi-omics
Breast cancer
BRCA1
BRCA2
therapy resistance
ISSN:2692-8205
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR-defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi) but they eventually acquire resistance. Preclinical studies yielded several PARPi resistance mechanisms that do not involve BRCA1/2 reactivation, but their relevance in the clinic remains elusive. To investigate which BRCA1/2-independent mechanisms drive spontaneous resistance in vivo, we combined molecular profiling with functional analysis of the HR status of matched PARPi-naïve and PARPi-resistant mouse mammary tumors harboring large intragenic deletions that prevent functional restoration of BRCA1/2. We observed restoration of HR in 64% of PARPi-resistant BRCA1-deficient tumors but none in the PARPi-resistant BRCA2-deficient tumors. Moreover, we found that 53BP1 loss is the prevalent resistance mechanism in HR-proficient BRCA1-deficient tumors, whereas resistance in BRCA2-deficient tumors is mainly induced by the loss of PARG. Our combined multi-omics analysis catalogued additional genes and pathways potentially involved in modulating PARPi response.
Bibliography:Competing Interest Statement: The authors have declared no competing interest.
ISSN:2692-8205
DOI:10.1101/2022.09.07.506927